BIO
Bio-Rad Laboratories, Inc.302.02
-5.90-1.92%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
FY Q3 '25
Key Stats
Market Cap
8.15BP/E (TTM)
-Basic EPS (TTM)
-24.01Dividend Yield
0%Recent Filings
8-K
Bio-Rad Q3 revenue edges up
Bio-Rad Laboratories reported Q3 2025 revenue of $653 million, up 0.5% from last year but down 1.7% on a currency-neutral basis, as constrained academic research and lower diabetes testing reimbursements in China pressured both life science and clinical diagnostics segments. Non-GAAP operating income rose to $77 million, aided by cost discipline, while a $495 million fair value loss on its Sartorius investment swung GAAP net income to a $342 million loss. Bio-Rad holds its full-year outlook for 0-1% currency-neutral revenue growth and 12-13% non-GAAP operating margin. Volatility in equity investments persists.
10-Q
Q3 FY2025 results
Bio-Rad's Q3 net sales edged up 0.5% y/y to $653.0M, with Life Science flat and Clinical Diagnostics up 0.6%, though currency neutral sales dipped 1.7% amid biotech funding squeezes and China reimbursement cuts. Gross margins slipped to 52.6% from 54.8%, hit by higher material costs and lower absorption, while operating income held steady at $65.3M. The quarter swung to a $341.9M net loss from $653.2M profit, driven by $495.3M fair-value losses on Sartorius holdings—net loss outpaced operating income by over 20% due to those changes and interest. Cash from operations hit $367.3M YTD, funding $218.5M Stilla buyout closed June 2025 for $257.7M (cash/contingent), adding $160.5M goodwill and $94.9M developed tech intangibles. Debt stands at $1.2B (3.3%/3.7% senior notes due 2027/2032), with $395.8M cash and full $200M revolver access. Bio-Rad stays liquid. Yet competition in diagnostics erodes pricing power.
8-K
Co-founder Alice Schwartz passes
Bio-Rad Laboratories announced the passing of co-founder and Director Emeritus Alice N. Schwartz on September 25, 2025, at age 99. Schwartz, who co-founded the company in 1952 with her husband and drove its expansion from specialty chemicals into clinical diagnostics via a pivotal 1960s thyroid test kit, served actively on the board until 2022. Her legacy of scientific passion endures. Bio-Rad generated $2.6 billion in 2024 revenues.
8-K
Bio-Rad unveils ddPCR innovations
Bio-Rad Laboratories hosted a webinar on August 26, 2025, spotlighting its Droplet Digital PCR portfolio as the market innovator since 2010, backed by over 12,000 peer-reviewed publications. The presentation highlights droplet-based technology's superior precision for applications in oncology, biopharma, and biosurveillance, positioning ddPCR to capture growth in the $600M absolute quantitation segment amid evolving needs beyond qPCR and NGS limitations. Bio-Rad's 490,000+ validated assays fuel seamless tech shifts. Forward-looking plans target accelerating customer adoption, yet actual results hinge on market risks.
10-Q
Q2 FY2025 results
Bio-Rad's Q2 sales edged up 2.1% y/y to $651.6M, with Life Science growing 4.9% on process chromatography strength while Clinical Diagnostics held flat amid China reimbursement cuts. Gross margins slipped to 53.0% from 55.6%, pressured by higher material costs and lower absorption, yet operating income fell less sharply to $77.1M from $101.5M. A $334.4M gain on Sartorius holdings flipped the prior year's $2.9B loss, driving net income to $317.8M and $11.67 diluted EPS from a $76.26 loss. Cash from operations hit $246.4M YTD, funding $216.7M for the Stilla acquisition—closed June 30 for $257.9M total (cash/contingent), adding $161.9M goodwill and $94.4M developed technology. Debt stands steady at $1.2B (3.3%/3.7% senior notes due 2027/2032), with $369.3M cash and $200M revolver availability. Free cash flow reached $166.3M YTD (derived). Restructuring costs mounted to $35.6M YTD. Sartorius volatility remains a key risk.
ABT
Abbott Laboratories
126.86-1.61
BDX
Becton, Dickinson and Company
196.39-3.70
BRKR
Bruker Corporation
44.96-0.71
BSX
Boston Scientific Corporation
92.95+0.76
DHR
Danaher Corporation
224.70-3.83
HBIO
Harvard Bioscience, Inc.
0.70-0.00
LAB
Standard BioTools Inc.
1.49-0.02
PACB
Pacific Biosciences of Californ
2.02-0.10
TECH
Bio-Techne Corp
57.44-1.25
TMO
Thermo Fisher Scientific Inc
570.16-5.75